HRP20140132T1 - Uporaba ulipristala za lijeäśenje uterinih fibroida - Google Patents

Uporaba ulipristala za lijeäśenje uterinih fibroida Download PDF

Info

Publication number
HRP20140132T1
HRP20140132T1 HRP20140132AT HRP20140132T HRP20140132T1 HR P20140132 T1 HRP20140132 T1 HR P20140132T1 HR P20140132A T HRP20140132A T HR P20140132AT HR P20140132 T HRP20140132 T HR P20140132T HR P20140132 T1 HRP20140132 T1 HR P20140132T1
Authority
HR
Croatia
Prior art keywords
cdb
uterine fibroids
group
ulipristal acetate
patient suffering
Prior art date
Application number
HRP20140132AT
Other languages
English (en)
Inventor
Erin Gainer
Lynnette Nieman
André Ulmann
Diana Blithe
Original Assignee
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer, National Institutes Of Health
Laboratoire Hra Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140132(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer, National Institutes Of Health, Laboratoire Hra Pharma filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer, National Institutes Of Health
Publication of HRP20140132T1 publication Critical patent/HRP20140132T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Claims (12)

1. Ulipristal acetat (17α-acetoksi-11β-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida.
2. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje oralnim putem.
3. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku tablete.
4. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema bilo kojem od zahtjeva 1-3 pri čemu se primjenjuje u dnevnoj dozi od 5 do 15 mg.
5. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 4 pri čemu se primjenjuje u dnevnoj dozi od 10 mg.
6. Ulipristal acetat za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida.
7. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183 za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje u obliku oralne doze kroz period od oko 2 do oko 4 mjeseca.
8. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 7 u ponavljanju od jednom godišnje.
9. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje toj bolesnici prije nego što će ići na operaciju maternice.
10. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu ulipristal acetat ili metabolit dalje djeluje kao kontraceptiv.
11. Ulipristal acetat, ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu ta bolesnica boluje od ili je podložna bolovanju od anemije.
12. Ulipristal acetat (17α-acetoksi-11β-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 za daljnju uporabu u prevenciji ili liječenju anemije u te bolesnice.
HRP20140132AT 2008-01-29 2014-02-11 Uporaba ulipristala za lijeäśenje uterinih fibroida HRP20140132T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids
PCT/EP2009/050961 WO2009095418A1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids

Publications (1)

Publication Number Publication Date
HRP20140132T1 true HRP20140132T1 (hr) 2014-05-09

Family

ID=40551565

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140132AT HRP20140132T1 (hr) 2008-01-29 2014-02-11 Uporaba ulipristala za lijeäśenje uterinih fibroida

Country Status (20)

Country Link
US (5) US8299050B2 (hr)
EP (2) EP2252301B1 (hr)
JP (2) JP5906016B2 (hr)
KR (2) KR101571400B1 (hr)
AU (1) AU2009209652B2 (hr)
BR (1) BRPI0907028B8 (hr)
CA (2) CA2713254C (hr)
CY (1) CY1116485T1 (hr)
DK (1) DK2252301T3 (hr)
ES (1) ES2450592T3 (hr)
HR (1) HRP20140132T1 (hr)
IL (2) IL207182A (hr)
MX (1) MX2010008270A (hr)
NZ (1) NZ587439A (hr)
PL (1) PL2252301T3 (hr)
PT (1) PT2252301E (hr)
SI (1) SI2252301T1 (hr)
TW (1) TWI445537B (hr)
WO (1) WO2009095418A1 (hr)
ZA (1) ZA201006049B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
KR102166867B1 (ko) * 2010-03-22 2020-10-19 앨러간 파마슈티컬스 인터내셔널 리미티드 항프로게스틴의 비독성 전달을 위한 조성물들과 그 방법들
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
WO2014050105A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
US20150320766A1 (en) * 2012-12-14 2015-11-12 Laboratoire Hra-Pharma Copper intrauterine device
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
EP2961412A4 (en) 2013-02-26 2016-11-09 Triact Therapeutics Inc CANCER THERAPY
NZ712984A (en) * 2013-04-10 2020-07-31 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
EP3223843B1 (en) * 2014-11-24 2019-06-19 Ramot at Tel-Aviv University Ltd. Pigment epithelium derived factor (pedf) for the treatment of uterine fibroids
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
EP4106530A1 (en) 2020-02-19 2022-12-28 Velfag Ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
JPH10512889A (ja) 1995-02-02 1998-12-08 シェーリング アクチェンゲゼルシャフト 機能不全性子宮出血を治療する医薬を製造するためのプロゲステロンアンタゴニスト
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6861415B2 (en) 1996-05-01 2005-03-01 The United States Of America As Represented By The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
KR20010032056A (ko) 1997-11-14 2001-04-16 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 황체 호르몬-항 황체 호르몬 투약법
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
EP1613640A4 (en) 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
WO2006010097A2 (en) 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
CA2623678A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
JP2010514793A (ja) * 2006-12-28 2010-05-06 レプロス セラピューティクス インコーポレイティド 抗プロゲスチンのバイオアベイラビリティを改善するための方法および製剤
WO2008129396A2 (en) * 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
PL2252301T3 (pl) 2014-07-31
US20090192130A1 (en) 2009-07-30
SI2252301T1 (sl) 2014-05-30
US20160022698A1 (en) 2016-01-28
JP6138838B2 (ja) 2017-05-31
CA2713254A1 (en) 2009-09-06
IL207182A0 (en) 2010-12-30
US9180133B2 (en) 2015-11-10
JP2015120711A (ja) 2015-07-02
BRPI0907028A8 (pt) 2019-08-13
EP2252301B1 (en) 2013-12-11
AU2009209652A1 (en) 2009-08-06
EP2252301A1 (en) 2010-11-24
EP2684565A1 (en) 2014-01-15
BRPI0907028B8 (pt) 2021-05-25
IL207182A (en) 2015-06-30
US8299050B2 (en) 2012-10-30
IL234149B (en) 2019-02-28
TW200944211A (en) 2009-11-01
ZA201006049B (en) 2011-05-25
US20170246189A1 (en) 2017-08-31
WO2009095418A1 (en) 2009-08-06
ES2450592T3 (es) 2014-03-25
CA2713254C (en) 2014-10-07
MX2010008270A (es) 2011-01-14
JP2011510949A (ja) 2011-04-07
NZ587439A (en) 2012-06-29
IL234149A0 (en) 2014-09-30
BRPI0907028A2 (pt) 2015-07-07
BRPI0907028B1 (pt) 2019-09-24
US9682088B2 (en) 2017-06-20
US8722653B2 (en) 2014-05-13
KR20150055626A (ko) 2015-05-21
PT2252301E (pt) 2014-02-24
US20140187525A1 (en) 2014-07-03
DK2252301T3 (en) 2014-02-17
US20130023506A1 (en) 2013-01-24
AU2009209652B2 (en) 2013-03-21
CY1116485T1 (el) 2017-03-15
CA2857798A1 (en) 2009-09-06
EP2684565B1 (en) 2019-10-02
TWI445537B (zh) 2014-07-21
KR101571400B1 (ko) 2015-11-24
JP5906016B2 (ja) 2016-04-20
KR20110021709A (ko) 2011-03-04

Similar Documents

Publication Publication Date Title
HRP20140132T1 (hr) Uporaba ulipristala za lijeäśenje uterinih fibroida
Simmons et al. Hormonal contraception and obesity
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
JP2013231087A5 (hr)
HRP20221064T1 (hr) Oralne formulacije citidinskih analoga i postupci njihove uporabe
WO2010033188A2 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
JP2013514984A5 (hr)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
BRPI0414311A (pt) formas de dosagem de liberação controlada
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
HRP20180942T1 (hr) Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima
BRPI0611443B8 (pt) medicamento compreendendo gestágeno e/ou estrógeno e 5-metil-(6s)-tetrahidrofolato, seu uso e seu processo de formulação, e kit
RU2011103136A (ru) Фармацевтическая композиция на основе тонкоизмельченного прогестерона и ее применения
CN101468039B (zh) 一种治疗口腔粘膜病的复方双层缓释药膜的制备方法
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
HRP20171678T1 (hr) Postupci za smanjenje prejedanja ili kompulzivnog jedenja
TWI351960B (en) Multiphase product for contraception based on a na
HRP20200142T1 (hr) Postupci i sastavi za liječenje depresije uporabom ciklobenzaprina
CN102895524B (zh) 一种治疗妇科炎症的组合药物
HRP20230762T1 (hr) Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
HRP20090256T1 (hr) Upotreba estradiolvalerata i dienogesta za oralno liječenje disfunkcionalnog uterinog krvarenja u kontracepcijskom postupku
JP2008525317A5 (hr)
ALHarthi et al. Photobiomodulation for managing “Dry Socket”: A randomised controlled trial
JP6158077B2 (ja) ヘルペス感染症の予防措置及び治療措置のためのピロキシカム
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento